ArticleEuropean heart journal. Cardiovascular Imaging2025
Derivation and validation of an artificial intelligence-based plaque burden safety cut-off for long-term acute coronary syndrome from coronary computed tomography angiography.
Article in European heart journal. Cardiovascular Imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07565805 (Bern Intarcoronary Optical Coherence Tomography and Coronary Computed Tomography Angiography Registry), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bern Intarcoronary Optical Coherence Tomography and Coronary Computed Tomography Angiography Registry
Who cites it
4 citing papers in PubMed.
- Age and sex specific coronary plaque characteristics among South Asians: Insights from the DILWALE CTA study.American journal of preventive cardiology · 2026Article
- Association of AI-assisted quantitative coronary plaque burden and CT-derived fractional flow reserve with major adverse cardiovascular events.BMC medical imaging · 2026Article
- Coronary Computed Tomography and Artificial Intelligence-based Plaque Analysis.Current atherosclerosis reports · 2026Review
- Prognostic implications of quantified coronary atherosclerosis and myocardial perfusion in diabetes.Cardiovascular diabetology · 2025Observational
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
aimsArtificial intelligence (AI) has enabled accurate and fast plaque quantification from coronary computed tomography angiography (CCTA). However, AI detects any coronary plaque in up to 97% of patients. To avoid overdiagnosis, a plaque burden safety cut-off for future coronary events is needed. METHODS AND
resultsPercent atheroma volume (PAV) was quantified with AI-guided quantitative computed tomography in a blinded fashion. Safety cut-off derivation was performed in the Turku CCTA registry (Finland), and pre-defined as ≥90% sensitivity for acute coronary syndrome (ACS). External validation was performed in the Amsterdam CCTA registry (the Netherlands). In the derivation cohort, 100/2271 (4.4%) patients experienced ACS (median follow-up 6.9 years). A threshold of PAV ≥ 2.6% was derived with 90.0% sensitivity and negative predictive value (NPV) of 99.0%. In the validation cohort 27/568 (4.8%) experienced ACS (median follow-up 6.7 years) with PAV ≥ 2.6% showing 92.6% sensitivity and 99.0% NPV for ACS. In the derivation cohort, 45.2% of patients had PAV < 2.6 vs. 4.3% with PAV 0% (no plaque) (P < 0.001) (validation cohort: 34.3% PAV < 2.6 vs. 2.6% PAV 0%; P < 0.001). Patients with PAV ≥ 2.6% had higher adjusted ACS rates in the derivation [Hazard ratio (HR) 4.65, 95% confidence interval (CI) 2.33-9.28, P < 0.001] and validation cohort (HR 7.31, 95% CI 1.62-33.08, P = 0.010), respectively.
conclusionThis study suggests that PAV up to 2.6% quantified by AI is associated with low-ACS risk in two independent patient cohorts. This cut-off may be helpful for clinical application of AI-guided CCTA analysis, which detects any plaque in up to 96-97% of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.